In an unusual move the British Medical Journal has gone against the establishment by daring to publish something that breaks the Covid narrative to some degree with an article titled:
Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial
In the last 18+ months we have see the reputation of one institute after another been thrashed and that includes the scientific establishment as they kow tow to the global tyranny to push through the Covid scamdemic. Just last year we saw the presitigious Lancet journal publish a completely fraudulent article purporting to show hydroxychloroquinewas not effective when it turned out the data was fabricated and they were forced to re-withdraw the paper yet the WHO used the paper as a reason to call a halt worldwide at the time to the use of the highly effect drug. That separate story is told quite well in this interview with Dr James Todaro at https://delingpole.podbean.com/e/dr-james-todaro/
There have been numerous other blatant frauds carried out and it has become quite clear that scientific establishment is beholden to corporate interests and big capital as any other and it is against that background then that it is so unusual for the BMJ to defy these powerful interests
The British Medical Journal, BMJ reports
Revelations of poor practices at a contract research company helping to carry out Pfizer’s pivotal covid-19 vaccine trial raise questions about data integrity and regulatory oversight. Paul D Thacker reports
But, for researchers who were testing Pfizer’s vaccine at several sites in Texas during that autumn, speed may have come at the cost of data integrity and patient safety. A regional director who was employed at the research organisation Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial. Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding. After repeatedly notifying Ventavia of these problems, the regional director, Brook Jackson, emailed a complaint to the US Food and Drug Administration (FDA). Ventavia fired her later the same day. Jackson has provided The BMJ with dozens of internal company documents, photos, audio recordings, and emails.
Read the article at the BMJ here